Stephanie V. Blank

Stephanie V. Blank

Auto-generated profile, based on publicly available information

Stephanie V. Blank

Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
JCJing-Yi Chern
Jing-Yi Chern
SLSarah Lee
Sarah Lee
MFMelissa K. Frey
Melissa K. Frey
JLJessica Lee
Jessica Lee
SBStephanie V. Blank
Stephanie V. Blank
Chern JY, et al. J Gynecol Oncol. 2018 Aug;30:e60. https://doi.org/10.3802/jgo.2019.30.e60

1 March 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
NMNigel Madden
Nigel Madden
MFMelissa K. Frey
Melissa K. Frey
LJLiJin Joo
LiJin Joo
JLJessica Lee
Jessica Lee
KMKelsey Musselman
Kelsey Musselman
BPBhavana Pothuri
Bhavana Pothuri

6 January 2022 in Gynecologic Oncology
Verified
Journal Article
Open access
STSarah Temkin
Sarah Temkin
ECE. Chapman-Davis
E. Chapman-Davis
NNNavya Nair
Navya Nair
DCD.E. Cohn
D.E. Cohn
JHJ.F. Hines
J.F. Hines
SBS.V. Blank
S.V. Blank
Equality, equity, and parity in the workplace are necessary to optimize patient care across all aspects of medicine. Gender-based inequities remain an obstacle to quality of care, including within the now majority women subspecialty of gynecologic oncology. The results of the 2020 SGO State of the Society Survey prompted this evidence-based review. Evidence related to relevant aspects of the clinical care model by which women with malignancies are cared for is summarized. Recommendations are made that include ways to create work environments where all members of a gynecologic oncology clinical care team, regardless of gender, can thrive. These recommendations aim to improve equality and equity within the specialty and, in doing so, elevate the care that our patients receive.

13 March 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
CGCorey M. Gill
Corey M. Gill
MDMegan R. D’aNdrea
Megan R. D’aNdrea
STShannon Tomita
Shannon Tomita
JSJessa Suhner
Jessa Suhner
MUMelissa Umphlett
Melissa Umphlett
VKValentin Kolev
Valentin Kolev
Introduction The density and distribution of the tumor immune microenvironment associated with brain metastases (BM) from gynecologic malignancies are unknown and have not been previously reported. We sought to describe the clinical features of a cohort of patients with BM from gynecologic malignancies and to characterize the tumor immune microenvironment from available archival surgical specimens. Methods We performed a retrospective review of electronic medical records from 2002 to 2018 for patients with BM from gynecologic malignancies. Data on patient characteristics, treatment regimens, and clinical outcomes were procured. CD4, CD8, CD45RO, CD68, CD163, and FOXP3 immunohistochemistry were evaluated from available archival surgical specimens from primary disease site and neurosurgical resection. Results A cohort of 44 patients with BM from gynecologic malignancies was identified, 21 (47.7%) endometrial primaries and 23 (52.3%) ovarian primaries. Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) were evaluated in 13 primary cases and 15 BM cases. For the 13 primary cases, CD4+ TILs were evident in 76.9% of cases, CD8+ in 92.3%, CD45RO+ in 92.3%, and FOXP3+ in 46.2%, as well as CD68+ TAMs in 100% and CD163+ in 100%. For the 15 BM cases, CD4+ TILs were evident in 60.0% of cases, CD8+ in 93.3%, CD45RO+ in 73.3%, and FOXP3+ in 35.7%, as well as CD68+ TAMs in 86.7% and CD163+ in 100%. Conclusion An active tumor immune microenvironment is present with similar distribution in the primary disease site and BM from patients with gynecologic malignancies.

23 November 2021 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
ALAurora Leibold
Aurora Leibold
KPKatyayani Papatla
Katyayani Papatla
KZKristen P. Zeligs
Kristen P. Zeligs
SBStephanie V. Blank
Stephanie V. Blank

26 September 2022 in JMIR Formative Research
Verified
Journal Article
Open access
TCTara Coffin
Tara Coffin
Deborah J. BowenDeborah J. Bowen
Deborah J. Bowen
KLKaren Lu
Karen Lu
ESElizabeth M Swisher
Elizabeth M Swisher
NRNadine Rayes
Nadine Rayes
RLRebecca Lechner
Rebecca Lechner
Background: Strong participant recruitment practices are critical to public health research but are difficult to achieve. Traditional recruitment practices are often time consuming, costly, and fail to adequately target difficult-to-reach populations. Social media platforms such as Facebook are well-positioned to address this area of need, enabling researchers to leverage existing social networks and deliver targeted information. The MAGENTA (Making Genetic Testing Accessible) study aimed to improve the availability of genetic testing for hereditary cancer susceptibility in at-risk individuals through the use of a web-based communication system along with social media advertisements to improve reach. Objective: This paper is aimed to evaluate the effectiveness of Facebook as an outreach tool for targeting women aged ≥30 years for recruitment in the MAGENTA study. Methods: We designed and implemented paid and unpaid social media posts with ongoing assessment as a primary means of research participant recruitment in collaboration with patient advocates. Facebook analytics were used to assess the effectiveness of paid and unpaid outreach efforts. Results: Over the course of the reported recruitment period, Facebook materials had a reach of 407,769 people and 57,248 (14.04%) instances of engagement, indicating that approximately 14.04% of people who saw information about the study on Facebook engaged with the content. Paid advertisements had a total reach of 373,682. Among those reached, just <15% (54,117/373,682, 14.48%) engaged with the page content. Unpaid posts published on the MAGENTA Facebook page resulted in a total of 34,087 reach and 3131 instances of engagement, indicating that around 9.19% (3131/34,087) of people who saw unpaid posts engaged. Women aged ≥65 years reported the best response rate, with approximately 43.95% (15,124/34,410) of reaches translating to engagement. Among the participants who completed the eligibility questionnaire, 27.44% (3837/13,983) had heard about the study through social media or another webpage. Conclusions: Facebook is a useful way of enhancing clinical trial recruitment of women aged ≥30 years who have a potentially increased risk for ovarian cancer by promoting news stories over social media, collaborating with patient advocacy groups, and running paid and unpaid campaigns. Trial Registration: ClinicalTrials.gov NCT02993068; https://clinicaltrials.gov/ct2/show/NCT02993068